CA2368618A1 - Method of enhancing the efficacy of anti-tumor agents - Google Patents

Method of enhancing the efficacy of anti-tumor agents Download PDF

Info

Publication number
CA2368618A1
CA2368618A1 CA002368618A CA2368618A CA2368618A1 CA 2368618 A1 CA2368618 A1 CA 2368618A1 CA 002368618 A CA002368618 A CA 002368618A CA 2368618 A CA2368618 A CA 2368618A CA 2368618 A1 CA2368618 A1 CA 2368618A1
Authority
CA
Canada
Prior art keywords
tumor agent
erythropoietin
cisplatin
hematocrit
elevator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002368618A
Other languages
French (fr)
Other versions
CA2368618C (en
Inventor
M. Steven Piver
David F. Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368618A1 publication Critical patent/CA2368618A1/en
Application granted granted Critical
Publication of CA2368618C publication Critical patent/CA2368618C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method for enhancing the effect of anti-tumor agents on solid tumors is provided. The method comprises administering to an individual an anti-tumor agent and a hematocrit elevator. The hematocrit elevator may be administered before or concurrently with the anti-tumor agent.

Claims (13)

1. A method of improving the efficacy of an anti-tumor agent comprising the steps of administering to an individual in need of treatment (a) a chemotherapeutically effective amount of the anti-tumor agent; and (b) a hematocrit elevator, wherein the combination of the anti-tumor agent and the hematocrit elevator has a synergistic anti-tumor effect.
2. The method of claim 1, wherein the anti-tumor agent comprises a platinum compound.
3. The method of claim 2, wherein the anti-tumor agent is a malonato platinum compound.
4. The method of claim 3, wherein the malonato platinum compound is selected from the group consisting of cisplatin and carboplatin.
5. The method of claim 4, wherein the platinum compound is cisplatin.
6. The method of claim 4, wherein the platinum compound is carboplatin.
7. The method of claim 1, wherein the hematocrit elevator is selected from the group consisting of erythropoietin and erythropoietin-like substance.
8. The method of claim 7, wherein the hematocrit elevator is erythropoietin.
9. The method of claim 8, wherein the hematocrit elevator is an erythropoietin-like substance.
10. The method of claim 1, wherein the anti-tumor agent is cisplatin and the hematocrit elevator is erythropoietin.
11. The method of claim 10, wherein the cisplatin is administered in a dose of between 25 mg/m2 to 300 mg/m2.
12. The method of claim 11, wherein the cisplatin is administered in a dose of between 50 mg/m2 to 100 mg/m2.
13. The method of claim 1, wherein the hematocrit elevator is administered prior to the anti-tumor agent.
CA2368618A 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents Expired - Fee Related CA2368618C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/300,124 1999-04-27
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
CA2368618A1 true CA2368618A1 (en) 2000-11-02
CA2368618C CA2368618C (en) 2011-03-01

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2368618A Expired - Fee Related CA2368618C (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Country Status (18)

Country Link
US (3) US6171620B1 (en)
EP (1) EP1212068A4 (en)
JP (1) JP2002542296A (en)
KR (1) KR100693796B1 (en)
CN (1) CN1188137C (en)
AU (1) AU781301B2 (en)
BG (1) BG64940B1 (en)
BR (1) BR0010082A (en)
CA (1) CA2368618C (en)
HU (1) HUP0200840A3 (en)
IL (1) IL146012A0 (en)
MX (1) MXPA01010899A (en)
NO (1) NO20015227L (en)
NZ (1) NZ514521A (en)
PL (1) PL350918A1 (en)
RU (1) RU2271829C2 (en)
WO (1) WO2000064455A1 (en)
ZA (1) ZA200108012B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001250221B2 (en) 2000-04-26 2006-07-06 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
ATE466085T1 (en) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES
EP2368553B1 (en) 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
DE10361813A1 (en) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Using hematopoietic growth factors for structural regeneration of tissue, useful e.g. for treating liver damage and wounds
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
JP2010510794A (en) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド Modified erythropoietin polypeptide and therapeutic use thereof
MX351611B (en) 2007-03-29 2017-10-20 Wyeth Llc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
JP5461386B2 (en) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ,インコーポレーテッド Peripheral opioid receptor antagonists and uses thereof
ES2540551T3 (en) 2007-03-29 2015-07-10 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
EP2730578A1 (en) 2008-02-06 2014-05-14 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnal trexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (en) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Pharmaceutical set and application of erythropoietin and of the Bruton kinase inhibitor
JPWO2019083023A1 (en) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 Compositions for use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (en) * 1988-03-03 1997-07-16 中外製薬株式会社 Bone marrow dysfunction anemia treatment
JPH1067678A (en) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd Medicinal composition for treating liver disease
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
HUP0200840A2 (en) 2002-07-29
IL146012A0 (en) 2002-07-25
CN1188137C (en) 2005-02-09
EP1212068A1 (en) 2002-06-12
KR100693796B1 (en) 2007-03-12
US6426094B2 (en) 2002-07-30
BG64940B1 (en) 2006-10-31
AU781301B2 (en) 2005-05-12
RU2271829C2 (en) 2006-03-20
CA2368618C (en) 2011-03-01
MXPA01010899A (en) 2003-06-24
BG106057A (en) 2002-04-30
JP2002542296A (en) 2002-12-10
KR20020000557A (en) 2002-01-05
NO20015227L (en) 2001-12-27
US20010000730A1 (en) 2001-05-03
NZ514521A (en) 2003-07-25
BR0010082A (en) 2002-01-15
US6171620B1 (en) 2001-01-09
ZA200108012B (en) 2003-03-26
PL350918A1 (en) 2003-02-10
CN1352561A (en) 2002-06-05
HUP0200840A3 (en) 2003-04-28
AU4486300A (en) 2000-11-10
US20020198153A1 (en) 2002-12-26
US6620779B2 (en) 2003-09-16
NO20015227D0 (en) 2001-10-25
EP1212068A4 (en) 2007-03-14
WO2000064455A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
CA2368618A1 (en) Method of enhancing the efficacy of anti-tumor agents
CA2326761A1 (en) Antitumor agent
RU2001131894A (en) METHOD FOR INCREASING EFFICIENCY OF ANTITUMOR AGENTS
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
KR900002784A (en) Pharmaceutical binding agents for use in antitumor therapy
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
CA2261500A1 (en) Stable oxaliplatin solutions and their use in cytostatic antineoplastic treatment
NO20024586D0 (en) Method and preparations to prevent hormone-induced side effects
TR199701150T1 (en) A pharmaceutical composition containing N-chlorophenyl carbamates, N-chlorophenylthiocarbamates and N-phosphonoglycine derivatives for inhibiting the development of viruses and cancers in mammals.
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
CA2002859A1 (en) Method of treating epithelial disorders
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
CA2673449A1 (en) A combination comprising combretastatin and anticancer agents
RU99107569A (en) PHARMACEUTICAL COMPOSITIONS Possessing Antimicrobial Activity
AU3245489A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
WO2005039554A3 (en) Therapeutic use of methionine for the treatment or prevention of mucositis
CA2334527A1 (en) Combination of selenium-containing compounds with cytostatics
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
MY122052A (en) Method of treating tourette''s syndrome
CA2206566A1 (en) Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
CA2283739A1 (en) Ascorbic acid as an adjuvant in treatment of malignant tumors by chemotherapy and radiotherapy
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
DK0669826T3 (en) (-) - Metrifonate-containing drug

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed